Candel Therapeutics, Inc. Common Stock (CADL) is a publicly traded Healthcare sector company. As of October 22, 2026, CADL trades at $8.53 with a market cap of $661.12M and a P/E ratio of -13.68. CADL moved +1.90% today. Year to date, CADL is +53.86%; over the trailing twelve months it is +52.46%. Its 52-week range spans $4.25 to $14.00. Analyst consensus is strong buy with an average price target of $20.80. Rallies surfaces CADL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for CADL, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $8.53 |
| Market Cap | $661.12M |
| P/E Ratio | -13.68 |
| EPS | $-0.72 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.00 |
| 52-Week Low | $4.25 |
| Volume | 11.64K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-38.18M |
| Gross Margin | 0.00% |
5 analysts cover CADL: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.80.